An Executive Informational Overview (EIO) is now available on Celsion Corporation, a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Snapshot of Celsion Corporation
Celsion Corporation (“Celsion” or “the Company”) is a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. Through the application of its two distinct nanoparticle-based technology platforms, Celsion has developed a robust pipeline that includes two clinical programs: (1) GEN-1, a DNA-based immunotherapy in a Phase I/II study for the treatment of Stage III/IV ovarian cancer. GEN-1 is a non-viral, synthetic delivery platform that facilitates the localized secretion of interleukin-12 (IL-12)—an immune protein that plays a key role in generating an immune response against cancer—into the tumor region; and (2) ThermoDox®, a heat-activated nanoparticle encapsulation of doxorubicin (a widely used chemotherapeutic agent) in a Phase III clinical trial for the treatment of hepatocellular cancer (HCC)/primary liver cancer. When heated through the application of heat-based treatments, ThermoDox® changes structure, creating openings that release doxorubicin directly into the tumor. Through investigator sponsored studies, Celsion is further supporting clinical studies to expand the application of its ThermoDox® technology platforms into other cancer indications in breast, pancreatic, and bladder cancer.
.
Key Points of Celsion Corporation
*******************************************
Visit our Corporate Profile and Investment Highlights pages
for the latest research on Celsion Corporation
*******************************************